About AccuTheranostics
AccuTheranostics is a company based in Buffalo (United States) founded in 2012 by Steven Cerne, Arvind Thakur, and Sherry Bradford. AccuTheranostics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Castle Biosciences and Personalis, among others.
- Headquarter Buffalo, United States
- Founders Steven Cerne, Arvind Thakur, Sherry Bradford
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$50 K (USD), Grant
Sep 12, 2016
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of AccuTheranostics
Investors in AccuTheranostics
AccuTheranostics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Launch NY.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Launch NY is focused on supporting high-growth startups in Upstate New York.
|
Locked | Locked | Locked |
Investor details for AccuTheranostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AccuTheranostics
Investment portfolio details for AccuTheranostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AccuTheranostics
Detailed financials for AccuTheranostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Accutheranostics Comparisons
Peer comparison for AccuTheranostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AccuTheranostics
AccuTheranostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Castle Biosciences and Personalis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of AccuTheranostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Accutheranostics
Complete news archive for AccuTheranostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AccuTheranostics
AccuTheranostics was founded in 2012 and raised its 1st funding round 4 years after it was founded.
AccuTheranostics is headquartered in Buffalo, United States. It is registered at Buffalo, New York, United States.
Steven Cerne is the current CEO of AccuTheranostics. They have also founded this company.
AccuTheranostics was founded in 2012 and is headquartered in Buffalo, United States. The company operates in the healthcare sector, focusing on oncology and personalized medicine. Laboratory tests, including the ChemoFit assay, are developed to evaluate individual patient responses to chemotherapy drugs. These services assist medical professionals in selecting appropriate treatments for cancer patients based on biological data.
AccuTheranostics's top competitors include Personalis, Poseida Therapeutics and Denali Therapeutics.
AccuTheranostics has 1 investor. Key investors include Launch NY.